Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $28,507 | -$237,892 | -$291,754 | -$287,100 |
| Dep. & Amort. | $5,276 | $3,791 | $3,699 | $3,454 |
| Deferred Tax | $0 | $0 | $0 | $9,438 |
| Stock-Based Comp. | $27,802 | $0 | $50,737 | $51,364 |
| Change in WC | $55,894 | -$36,826 | -$79,257 | $42,360 |
| Other Non-Cash | -$137,919 | $96,043 | $75,451 | $143,052 |
| Operating Cash Flow | -$20,440 | -$174,884 | -$241,124 | -$37,432 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$286 | -$2,039 | -$1,289 |
| Net Acquisitions | $0 | $845 | $0 | $1,289 |
| Inv. Purchases | $0 | -$19,507 | -$127,382 | -$182,485 |
| Inv. Sales/Matur. | $14,888 | $157,642 | $0 | $181,364 |
| Other Inv. Act. | $215,433 | $5,946 | -$37,429 | -$137,289 |
| Investing Cash Flow | $230,321 | $144,640 | -$166,850 | -$138,410 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$223,408 | $0 | $49,929 | -$672 |
| Stock Issued | $1,455 | $74,221 | $6,358 | $40,903 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $34,979 | -$4,621 | -$1,961 | $11,648 |
| Financing Cash Flow | -$186,974 | $69,600 | $54,326 | $51,879 |
| Forex Effect | $0 | -$12 | $0 | $0 |
| Net Chg. in Cash | $22,907 | $39,344 | -$353,648 | -$123,963 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $103,343 | $63,547 | $417,635 | $541,598 |
| End Cash | $126,250 | $102,891 | $63,987 | $417,635 |
| Free Cash Flow | -$20,440 | -$175,170 | -$243,163 | -$38,721 |